National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

< Back to Main
Page Options
Print This Page
E-Mail This Document
Browse by Cancer Type
Breast Cancer

Lung Cancer

Prostate Cancer

More Results
Search Trial Results

      
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
Related Pages
Multiple Myeloma/Other Plasma Cell Neoplasms
NCI's gateway for information about multiple myeloma and other plasma cell neoplasms.

Search for Clinical Trials
NCI's PDQ® registry of cancer clinical trials.
Multiple Myeloma Trial Results
1.  Thalidomide Effective in Multiple Myeloma
(Posted: 03/15/2006, Updated: 09/16/2008) - In the March 9, 2006, issue of the New England Journal of Medicine, researchers report superior event-free and complete response rates when the drug thalidomide was used before and during primary therapy for multiple myeloma. Longer follow-up showed a survival benefit for some patients, as well.

2.  Bortezomib Approved for First-Line Treatment of Multiple Myeloma
(Posted: 09/11/2008) - The targeted drug bortezomib, when added to standard therapy (melphalan and prednisone), significantly improves time to progression and overall survival in patients with newly diagnosed multiple myeloma, according to the August 28, 2008, New England journal of Medicine.

3.  Thalidomide a Beneficial Option for Elderly Multiple Myeloma Patients
(Posted: 02/12/2008) - Patients aged 75 and over with newly diagnosed multiple myeloma who received the drug thalidomide in addition to standard therapy (melphalan and prednisone) survived longer than patients who received standard therapy plus a placebo, according to clinical trial results presented at the 2007 annual meeting of the American Society of Hematology.

4.  Drug Combination Shows Benefit in Relapsed/Refractory Multiple Myeloma
(Posted: 08/28/2007) - A new combination treatment should be another standard of care for patients with relapsed or refractory multiple myeloma, according to the Sept. 1, 2007, Journal of Clinical Oncology.

5.  Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
(Posted: 04/04/2007) - Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, a cancer typically found in bone marrow, has shown that use of a low dose of the steroid dexamethasone (Decadron ®), in combination with lenalidomide (Revlimid ®) is associated with improved survival when compared to a treatment regimen with lenalidomide and a higher, standard dose of dexamethasone.
1 2 3 4   Next >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov